Patents & Populism

Patent Session 8C


Robert J. Goldman

Ropes & Gray LLP, Palo Alto


Hon. Dr. Annabelle Bennett

5 Wentworth, Sydney
Patents & Innovation
The highest appellate courts do not seem to agree on whether patents harm, or chill innovation or promote it. Is the answer evidence-based or depend on one’s views of populism?

Jamie Love

Knowledge Ecology International, Washington, D.C.

Policies Concerning Patents on Federally Funded Biomedical Inventions Need a Reboot

There is considerable public support for government funding of biomedical research, but not much government support for the public interest in the management of patents on the research. An astounding lack of transparency of licensing practice, excessive pricing of drugs, and restrictive licensing of patents are allowed by the NIH, the Army and other federal agencies that fund biomedical research, as though the taxpayers have no legitimate interests in the management of the R&D resources they fund. Recent controversies include the CRISPR gene editing technologies, expensive drugs such as Spinraza or Xtandi, and the federally funded vaccines for the Zika virus. If the Executive branch of the government is unwilling to implement reforms, the Congress should act.


Hon. Mr. Justice Birss

Chancery Division, High Court, London

Hon. Denny Chin

U.S. Court of Appeals for the Second Circuit, New York

John Lee

Gilbert + Tobin, Sydney

Hon. Pauline Newman

U.S. Court of Appeals for the Federal Circuit, Washington, D.C.

David Rosenberg

Vice President, IP Policy, GlaxoSmithKline (GSK), London
Fordham IP Institute